FOR IMMEDIATE RELEASE. News Abbot and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease ABBOTT PARK, Ill. and IRVING, Texas, September 23, 2010 – Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). Under the terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets. Reata will receive upfront and near term cash payments of $450 million for the licensing rights to bardoxolone and a minority equity investment in the company. Upon completion of certain development and approval objectives for bardoxolone and other molecules in the licensed territories, Reata will receive additional milestone payments. Reata also will receive royalties on any future product sales in the Abbott territories. Additionally, Abbott obtains rights to develop and commercialize certain other Reata compounds for chronic kidney disease, and for cardiovascular and metabolic indications, in these territories. “Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis,” said Xxxx Xxxxxxx, M.D., senior vice president, pharmaceuticals, research and development, Abbott. “This agreement builds on Xxxxxx’x existing experience in renal care, while adding a promising compound to our later-stage pipeline.” Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys. In two Phase 2 clinical trials, bardoxolone significantly improved kidney function in patients with advanced CKD and Type 2 diabetes. CKD currently affects more than 50 million adults worldwide, and the number of patients is rapidly increasing throughout the world. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. “Reata is very pleased to have Abbott as our partner and believe that...
FOR IMMEDIATE RELEASE. Infinity Contacts: Intellikine Contact: Investors: Xxxxxx Xxxxx, 000-000-0000 xxxxxx.xxxxx@xxxx.xxx Xxxxxxx Xxxxxxx, 000-000-0000 xxxxxxx@xxxxxxxxxxxxxxxxx.xxx Media: Xxxxxx Xxxxx, 000-000-0000 xxxxxx@xxxxxxxxxxxxxxxxxxxxx.xxx INFINITY AND INTELLIKINE ENTER AGREEMENT TO DEVELOP ORAL THERAPIES TARGETING PI3 KINASE DELTA, GAMMA – Infinity Uses Scientific Expertise and Financial Strength to Enter New Therapeutic Area – – Intellikine Retains Strategic Development and Commercial Rights in Oncology in Deal Valued Up to $488 Million – CAMBRIDGE, Mass. and LA JOLLA, Calif. – July 8, 2010 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine’s portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K). Among these inhibitors is INK1197, an orally available dual delta/gamma-specific inhibitor of PI3K for which clinical development in inflammatory diseases is expected to commence in 2011. Under the terms of the agreement, Intellikine will receive $13.5 million in initial license payments, committed research funding over the first two years of the relationship to identify additional novel delta, gamma and dual delta/gamma-specific inhibitors of PI3K for future development, up to $25 million in success-based milestones for the development of two distinct product candidates, and up to $450 million in success-based milestones for the approval and commercialization of two distinct products. In addition, Intellikine will be entitled to receive royalties upon successful commercialization of products licensed to Infinity. For products directed primarily to oncology indications, Intellikine will have the option, at the end of Phase 2 clinical development and upon payment of an option fee, to convert its royalty interest in U.S. sales into the right to share in 50% of profits and losses on U.S. development and commercialization, and to participate in up to 30% of the detailing effort for these products in the United States. The PI3Kdelta/gamma program licensed from Intellikine will be a part of Infinity’s existing strategic alliance with Mundipharma International Corporation Ltd. and will be governed by the same terms as Infinity’s internally-discovered programs. Such te...
FOR IMMEDIATE RELEASE. March 22, 2004 DRAXIS and Isotope Products Laboratories Sign Distribution Agreement Mississauga, Ontario, March 22, 2004—DRAXIMAGE Inc., the radiopharmaceutical subsidiary of DRAXIS Health Inc. (TSX: DAX, Nasdaq: DRAX), has concluded a distribution agreement with Isotope Products Laboratories (IPL), a California based producer of radioactive sources for Nuclear Medicine and radiography. DRAXIMAGE will market the full line of IPL medical products in Canada, including calibration references for imaging applications plus calibration sources for PET (Positron Emission Tomography) and SPET (Single Photon Emission Tomography), all well-established modes of diagnostic medical imaging. DRAXIMAGE will also introduce the Perflexion™, IPL's new flexible Cobalt-57 flood source, in Canada during the second quarter of 2004. About IPL IPL, based in Southern California, operates two manufacturing facilities employing professional staff, primarily chemists and engineers, and sells its products in over 30 countries around the world. IPL was founded in 1967 and operated as a privately held company for 32 years, specializing in radiation source production and custom source design. The company was acquired in 1999 by Xxxxxx & Xxxxxxx XX, of Berlin, Germany; a holding company involved in the development and production of low level radiation source products for industrial and medical applications and whose holdings include sister radiation source manufacturers, Bebig GmbH and Eurotope mbH. About DRAXMAGE Inc. XXXXXXXXX discovers, develops, manufactures and markets diagnostic imaging and therapeutic radiopharmaceuticals for the global marketplace. Products currently marketed by DRAXIMAGE include a line of lyophilized technetium-99m kits used in nuclear imaging procedures, a line of imaging and therapeutic products labeled with a variety of isotopes including radioiodine, and BrachySeed™, a next-generation brachytherapy implant for treating prostate cancer. DRAXIMAGE has several products in late-stage development, including three technetium-99m-based diagnostic imaging products: Fibrimage® for imaging deep vein thrombosis currently in Phase III, Amiscan™ for the early diagnosis of acute myocardial infarct currently in Phase II, and INFECTON™ for imaging infection, currently in Phase II. About DRAXIS Health Inc. DRAXIS Health Inc. (xxx.xxxxxx.xxx) is a specialty pharmaceutical company involved in the development, production, marketing and distribution of therapeutic and diagnostic ...
FOR IMMEDIATE RELEASE. Penguin Lands Marine Services Contract in the Middle East • S$4 million, two-year marine services contract awarded by Dubai’s Roads and Transport Authority (RTA) is part of the emirate’s S$500 million marine transport upgrading program • Penguin’s first third-party ship management contract affirms company’s 31-year experience in ferry operations • Middle East “toehold” entry strategy locks in stable revenue from modest capital commitments • Penguin Marine Boats Services (LLC) set up as a joint venture marine services company • Company well-positioned for additional contracts with RTA and neighbouring emirates Singapore, 4 July 2007 – Penguin Marine Offshore Services Pte. Ltd. ("PMOS"), the ferry chartering and overseas projects arm of Penguin Boat International Ltd. (“Penguin” or “the Group”), has been awarded a marine services contract by the government of Dubai’s Roads and Transport Authority (“RTA”) to manage modern Waterbus operations along Dubai Creek. The estimated S$2 million-a-year contract - secured in an international tender which fielded major ferry operators from Europe and Asia – will be executed by Penguin Marine Boats Services (LLC) (“PMBS”), which is a 49-51 joint venture owned respectively by PMOS and local partner, DEMAT Group. DEMAT Group, based in Sharjah, is a well-established marine and offshore services and equipment provider in the Middle East, with interests in aluminium ship design, ship building and ship owning, including crewboats and ferries. The scope of services in the RTA contract encompasses full management of the Waterbus operations, which includes systems implementation, crew management, vessel maintenance, procurement, security and safety management, environmental protection and training. Dubai’s RTA was formed in November 2005 to plan and execute major public land and sea transportation projects. The government agency is spending an estimated S$500 million to upgrade the emirate’s marine transport system in the initial phase. Under the RTA agreement, PMBS will operate and manage 10 new locally-built Waterbuses owned by RTA. Each Waterbus is about 12 metres long and can carry up to 36 passengers in air-conditioned comfort. According to RTA, the Waterbuses will initially transport about 2 million passengers a year, rising to 5 million eventually. In addition to the Waterbuses, there are close to 150 traditional wooden motorised Abras or Watertaxis, each with a capacity of up to 20 passengers, plying along Dubai Creek link...
FOR IMMEDIATE RELEASE. DATE: April 19, 2021 SUBJECT: Atlantic Broadband Cable Television Franchise Agreement
FOR IMMEDIATE RELEASE. Strategic Partnership Agreement His Little Ones, Inc. Austin, Texas, USA xxxxxx@xxxxxxxxxxxxx.xxx xxx.xxxxxxxxxxxxx.xxx His Little Ones, Inc. (HLO) has entered into a strategic partnership agreement with Romania Without Orphans Alliance (ARFO). The two organizations are joining efforts in their mission to find families for orphaned and abandoned children in Romania. HLO will lend support to ARFO by sharing best practices and providing fundraising strategies. ARFO will seek to increase the number of adoptions in Romania while promoting this partnership. ARFO will host HLO delegates for the purpose of making expertise available to our partners and advancing our shared mission.
FOR IMMEDIATE RELEASE. Media Contacts Baxter Xxxxx Xxxxx, (000) 000-0000 Xxxxxxx Xxxx, (000) 000-0000 Momenta Xxxx Xxxxxx, XxxXxxxxxx Biomedical Communications, (000) 000-0000 Investor Contacts Xxxxxx Xxxx Xxx Xxxxxx, (000) 000-0000 Xxxxx Xxxxxxxxx, (000) 000-0000 Momenta Xxxxxxx Xxxxxx, (000) 000-0000
FOR IMMEDIATE RELEASE. Media Contacts Xxx Xxxxxxxx SVP, Corporate Communications 503.727.4188 xxxxxxxxxxx@xxxxxxxxxx.xxx Xxxx Xxxx VP, Communications and Public Affairs Director 509.626.5348 xxxx.xxxx@xxxxxxxxxxxxxxxx.xxx Investor Contacts Xxx Xxxxxxxxxx EVP/Chief Financial Officer 503.727.4108 xxxxxxxxxxxxx@xxxxxxxxxx.xxx Xxxxxxx X. Xxxxxx EVP/Chief Financial Officer 509.227.0961 xxx.xxxxxx@xxxxxxxxxxxxxxxx.xxx STERLING FINANCIAL CORPORATION TO MERGE WITH UMPQUA HOLDINGS CORPORATION -Will create West Coast’s largest community bank with 394 locations in five states -Sterling shareholders to receive a fixed exchange ratio combination of 1.671 shares of Umpqua stock and $2.18 in cash per Sterling share Portland, Ore. and Spokane, Wash. – September 11, 2013 – Umpqua Holdings Corporation (UMPQ) and Sterling Financial Corporation (STSA) announced today that they have entered into a definitive agreement pursuant to which Sterling will merge with and into Umpqua. The transaction will have a total value of approximately $2.0 billion. The merger will result in the West Coast’s largest community bank with expanded geographic reach. The combined organization will have approximately $22 billion in assets, $15 billion in loans and $16 billion in deposits, with 5,000 associates and 394 stores across five states – Oregon, Washington, Idaho, California and Nevada. Umpqua and Sterling have also agreed to establish and fund a $10 million community foundation, underscoring their mutual commitment to serving their communities. Upon completion of the merger, the company will operate under the Umpqua Bank name and brand. It will continue to deliver the high-touch level of service that Umpqua and Sterling customers expect, with an expanded branch and ATM network and a broad range of products and expertise in retail, small business, private and corporate banking; asset and wealth management; and securities brokerage. Sterling Financial Corporation to Merge With Umpqua Holdings Corporation September 11, 2013 Umpqua Holdings Corporation will continue to be led by Xxx Xxxxx as president and CEO. Sterling president and CEO Xxxx Xxxxxx will join Umpqua Bank as co-president, with Umpqua Bank co-president Xxxx X’Xxxxx serving in the same capacity. “Together, Umpqua and Sterling will create something unique in the financial services industry, an organization that offers the products and expertise of a large bank but delivers them with the personal service and commitment of a community bank,” said Xxx Xxxxx. “W...
FOR IMMEDIATE RELEASE. LabCorp Contacts: Xxxxx Xxxxxxx (investors) +0 000-000-0000 Xxxxxxxx@xxxxxxx.xxx Xxx Xxx Xxxxx (media) +0 000-000-0000 Xxxxx@xxxxxxx.xxx LabCorp and Texas Association of Community Health Centers Extend Agreement for LabCorp to Be Exclusive Laboratory for Community Health Centers across Texas LabCorp Will Provide Enhanced Laboratory Services, With an Emphasis on Chronic Diseases, for Clinics Serving More Than One Million Patients Annually BURLINGTON, N.C., and AUSTIN, TEXAS, Jan. 15, 2019 - LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas Association of Community Health Centers, Inc. (TACHC) a private, non-profit association of approximately 75 community health centers with more than 500 service locations across Texas serving the most vulnerable populations, today announced that they have entered into an agreement for LabCorp to be the exclusive preferred laboratory for TACHC. This new agreement extends a relationship of more than 25 years and will provide enhanced laboratory services for more than one million patients who receive care from community health centers that are members of TACHC. LabCorp is a leading global life sciences company providing comprehensive laboratory services and end-to-end drug development services. TACHC is a private, non-profit association of approximately 75 community health centers with more than 500 service locations across Texas, which provides necessary health care services to the most vulnerable populations. “For many years, our member health centers have depended on LabCorp to provide high-quality testing services for the patients they serve and we are pleased to extend our relationship with LabCorp,” said Xxxx X. Xxxxxxx, Esq., executive director and general counsel for TACHC. “We look forward to enhancing the scope of laboratory services that will be available to our clinicians, which will provide immediate and long-term benefits for the patients we serve every day. In particular, we expect that the use of data analytics will help us better address health trends across the populations we serve and that new programs for chronic diseases will have a positive impact on the lives and health of our patients.” Under the new agreement, TACHC and LabCorp will use data analytics to identify population health trends, enabling focused community and individual outreach about screening, monitoring and treatment options for common health conditions. TACHC intends to make LabCorp’s Litholink clinical decision s...
FOR IMMEDIATE RELEASE. Date: May 26, 2020 Contact: Xxxx-Xxxxx Xxxxxx, Vice President, Corporate Communications Phone: (000) 000-0000 e-mail: xxxxxxx@xxxxx.xxx Fax: (000) 000-0000 MERIT MEDICAL ANNOUNCES AGREEMENT WITH STARBOARD Nominates Three Medical Device Industry Veterans – Xxxxx Xxxxxxxxx, Xxxxx Xxxxx and Xxxxx Xxxxx – for Election to the Board of Directors Announces Formation of Operating Committee to Review Margin Improvement Initiatives and Establish Targets SOUTH JORDAN, UTAH – Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has reached an agreement with Starboard Value LP and its affiliates (“Starboard”), an investment firm which owns approximately 8.7% of Merit’s outstanding common stock, pursuant to which the Company has nominated three new independent directors —Xxxxx Xxxxxxxxx, Xxxxx Xxxxx and Xxxxx X. Xxxxx—for election to the Merit Board of Directors at the Company’s upcoming 2020 Annual Meeting of Shareholders, scheduled to be held on June 22, 2020. In connection with the new director nominations, Merit also announced that Xxxxx X. Xxxxxx, Xxxxx X. Xxx, M.D. and Xxxxx X. Xxxx will not stand for re-election at the 2020 Annual Meeting and Xxxxxxxx Xxxxxx, M.D. will resign from the Board not later than immediately following the 2020 Annual Meeting. Merit’s Board intends to appoint Xx. Xxxx to fill the vacancy resulting from Xx. Xxxxxx’x resignation, which would place her in the class of directors standing for re-election at the 2021 Annual Meeting. Xxxx X. Xxxxxxx, a founder of Merit, has previously announced that he will not stand for re-election at the 2020 Annual Meeting. Following the 2020 Annual Meeting, Merit’s Board will be comprised of nine directors, seven of whom will be independent. Merit’s Board intends to select a new Lead Independent Director following the 2020 Annual Meeting.
